Family medicine content commonly referenced by physicians includes preventive care guidelines, chronic disease management recommendations, practice-changing clinical trials, cardiometabolic therapies, and validated screening tools. The following 10-item framework reflects widely used sources that inform primary care practice.

1. US Preventive Services Task Force (USPSTF) Colorectal Cancer Screening Recommendation — The USPSTF recommends colorectal cancer screening among patients aged 45 to 75 years at average risk and selective screening for patients aged 76 to 85 years based on overall health, prior screening history, and patient preferences.

2. Centers for Disease Control and Prevention (CDC) Adult Immunization Schedule — The CDC adult immunization schedule provides age- and risk-based vaccine recommendations for patients aged 19 years and older, including guidance on vaccine indications, dosing intervals, contraindications, precautions, and shared clinical decision-making considerations.

3. American Diabetes Association Standards of Care in Diabetes—2026 — The American Diabetes Association’s 2026 Standards of Care provide evidence-based recommendations across diabetes prevention; diagnosis; glycemic management; diabetes technology; obesity treatment; cardiovascular and kidney risk reduction; and care considerations for pediatric, pregnant, hospitalized, and older adult patients.

4. 2025 High Blood Pressure Guideline — The 2025 multisociety guideline updates recommendations for the prevention, detection, evaluation, and management of high blood pressure in adult patients and replaces the 2017 guideline. The guidance incorporates evidence from literature published through 2024 and is intended to support primary care and specialty clinicians managing patients with hypertension.

5. USPSTF Breast Cancer Screening Recommendation — The USPSTF recommends biennial screening mammography among women aged 40 to 74 years at average risk of breast cancer. The recommendation notes that evidence remains insufficient to assess the balance of benefits and risks iin screening women aged 75 years or older or using supplemental screening with breast ultrasonography or magnetic resonance imaging in women with dense breasts.

6. SELECT Trial — In the SELECT trial, once-weekly semaglutide reduced major adverse cardiovascular events compared with placebo in patients aged 45 years or older with cardiovascular disease and overweight or obesity without diabetes. The primary outcome included cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke.

7. DAPA-CKD Trial — In this trial, dapagliflozin reduced the risk of kidney function decline, end-stage kidney disease, and renal or cardiovascular mortality compared with placebo in patients with chronic kidney disease, regardless of type 2 diabetes status.

8. EMPA-KIDNEY Trial — In this trial, empagliflozin reduced the risk of kidney disease progression or cardiovascular mortality compared with placebo in patients with chronic kidney disease, including those with and without diabetes.

9. USPSTF Statin Recommendation for Primary Prevention — The USPSTF recommends statin therapy for patients aged 40 to 75 years with one or more cardiovascular risk factors and an elevated 10-year cardiovascular disease risk. The recommendation also supports selective statin use in those with lower estimated risk and notes insufficient evidence to assess statin initiation in patients aged 76 years or older.

10. Patient Health Questionnaire-9 — The Patient Health Questionnaire–9 is a commonly used depression screening tool in primary care that evaluates depressive symptoms, including suicidal thoughts. The Substance Abuse and Mental Health Services Administration notes that related materials provide recommended follow-up based on patient responses.

Sources: USPSTF, CDC, Diabetes Care, JACC Journals, JAMA, The New England Journal of Medicine, Substance Abuse and Mental Health Services Administration